BioPharmSignal logoBioPharmSignal

Biotech News

Innoviva Specialty Therapeutics Announces Oral Presentation Featuring New Analyses from the Zoliflodacin Pivotal Phase 3 Trial at IDWeek 2025

Innoviva (INVA)InnovivaClinical readout

Zoliflodacin, an investigational single-dose oral antibiotic for uncomplicated gonorrhea, to be featured in oral presentation with key subset analyses from pivotal global Phase 3 trial WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 20, 2025-- Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc.

Related news

INVAInnoviva2025-12-11 23:35 EST

Innoviva Specialty Therapeutics Announces Publication in The Lancet of Positive Zoliflodacin Phase 3 Data for the Treatment of Uncomplicated Urogenital Gonorrhea

FULCFulcrum Therapeutics2026-02-24 12:00 EST

Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

FULCFulcrum Therapeutics2026-02-17 13:00 EST

Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

EXELExelixis2026-05-19 12:00 EST

Exelixis Announces Clinical Development Collaboration with Merck for Phase 3 STELLAR-316 Pivotal Trial for Patients with Colorectal Cancer

ENTAEnanta Pharmaceuticals2026-04-13 11:00 EST

Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of Urticaria

EXELExelixis2026-05-30 14:00 EST

Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026

ZNTLZentalis2026-04-21 14:27 EST

Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer

PMVPPMV Pharmaceuticals2025-10-24 15:40 EST

PMV Pharmaceuticals Announces Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Phase 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation

GSKGSK plc2026-07-28 12:00 EST

GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026

View all latest news

Innoviva

Diversified Biopharmaceutical Model Innoviva combines a respiratory-royalty portfolio, a commercial critical-care and infectious-disease business, and strategic investments in healthcare companies. Respiratory Royalties The company receives royalties from respiratory medicines partnered with GSK, providing cash flows that support...

Recent company news

INVAInnoviva2026-08-05 20:05 EST

Innoviva Reports Second Quarter 2026 Financial Results; Highlights Recent Company Progress

INVAInnoviva2026-06-18 12:00 EST

Nortiva Bio Launches to Develop Long-Acting Oral Medicines

INVAInnoviva2026-06-16 12:00 EST

Innoviva Specialty Therapeutics Announces Distribution and Licensing Agreement with Dr. Reddy’s for XACDURO® in Select International Markets

INVAInnoviva2026-06-01 15:00 EST

Innoviva to Participate in Upcoming Investor Conferences

INVAInnoviva2026-05-06 20:05 EST

Innoviva Reports First Quarter 2026 Financial Results; Highlights Recent Company Progress

Stock data

Close
21.11 USD
Market cap
1.58B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States